MS Medications: Injectables, Orals, and Infusions

Multiple sclerosis medications span more than a dozen approved drugs across several distinct classes, from older self-injected interferons to newer oral pills and potent infusion therapies. The field has expanded rapidly since the first MS drug was approved in the 1990s, and the choices now range from relatively gentle immune modulators to aggressive treatments that essentially reset parts of the immune system. Which drug a person starts on, when to switch, and how to balance effectiveness against safety risks are among the most consequential decisions in MS care today.

The Main Categories of Disease-Modifying Therapy

Disease-modifying therapies, or DMTs, are the backbone of MS treatment. Unlike medications that manage individual symptoms, DMTs aim to slow the underlying disease process by dampening or redirecting the immune system’s attack on the brain and spinal cord. They fall into several broad groups based on how they are taken and how they work: self-injected therapies (interferons and glatiramer acetate), oral pills (fingolimod, dimethyl fumarate, teriflunomide, and newer agents), intravenous infusions (natalizumab, ocrelizumab, alemtuzumab), and pulsed immune reconstitution drugs (cladribine, alemtuzumab). Beyond these, corticosteroids are used short-term to manage acute relapses, symptom-management drugs address specific complaints like walking difficulty or spasticity, and a handful of emerging agents are in clinical trials.

Injectable Therapies

Interferon beta and glatiramer acetate were the first DMTs approved for relapsing-remitting MS and have been in use for roughly three decades. They are given by self-injection, either under the skin or into muscle, and are generally considered moderate-efficacy treatments. Interferons work by binding to receptors on immune cells and triggering a cascade that produces anti-inflammatory effects, while glatiramer acetate is a synthetic molecule that shifts the immune response away from the aggressive T cells that damage myelin.¹ One practical difference between the two: interferons quickly reduce signs of active inflammation visible on MRI, whereas glatiramer acetate works more slowly on that front but may have some protective effects on nerve cells inside the brain itself.²

These older injectables remain in use, but they are no longer first choice for many patients. Flu-like symptoms after interferon injections and injection-site reactions with glatiramer acetate are common quality-of-life complaints. More importantly, head-to-head data and real-world studies consistently show that newer, higher-efficacy drugs outperform them in preventing relapses and disability progression. Still, for people with mild disease activity or those who prefer a long safety track record, injectables remain a reasonable option.

Oral Medications

The arrival of oral DMTs in the 2010s changed the treatment experience for many people with MS. Instead of regular injections, patients could take a pill. Three major classes of oral therapy are now in wide use.

Fingolimod was the first oral DMT approved. It belongs to a class called S1P receptor modulators, which work by trapping certain immune cells inside the lymph nodes so they never reach the brain and spinal cord. Specifically, fingolimod blocks the signal that lymphocytes need to leave the lymph nodes, leading to a sharp drop in circulating immune cells and less inflammatory damage to the central nervous system.³ Several newer S1P modulators (siponimod, ozanimod, ponesimod) have since been approved, each with a slightly different receptor-binding profile that may reduce some of fingolimod’s side effects, such as the brief slowing of heart rate that requires monitoring after the first dose.⁴

Dimethyl fumarate works through a different mechanism. It activates antioxidant pathways inside cells and shifts the immune system toward a less inflammatory state, offering both anti-inflammatory and nerve-protective effects.⁵ Gastrointestinal upset and flushing are the most common early complaints, though they tend to fade over weeks. A newer formulation, diroximel fumarate, causes less stomach trouble while working through the same pathway.

Teriflunomide takes yet another approach: it blocks the production of building-block molecules that fast-dividing immune cells need to multiply, effectively putting the brakes on the activated lymphocytes driving MS inflammation.⁶ It is considered a moderate-efficacy option, roughly comparable to the older injectables, and is sometimes chosen when tolerability and convenience are priorities over maximal disease suppression.

Infusion Therapies

For people with highly active MS or those who break through milder treatments, intravenous infusion therapies offer some of the strongest disease suppression available.

Natalizumab was the first high-efficacy infusion approved for relapsing MS. It works by physically blocking immune cells from sticking to the blood-brain barrier, the protective lining that separates the bloodstream from the brain. Without that sticky grip, inflammatory T cells cannot cross into the central nervous system to cause damage.⁷ It is highly effective at reducing relapses, but it carries a specific safety concern discussed below.

Ocrelizumab targets B cells by binding to a protein called CD20 on their surface, selectively destroying them. This was a milestone: it proved that B cells play a central role in MS, not just the T cells researchers had long focused on. Ocrelizumab was also the first therapy shown to slow disability progression in primary progressive MS, a form of the disease that had no proven treatment before its approval.⁸ It is given as an infusion roughly every six months.⁹

Immune Reconstitution Therapies

Alemtuzumab and cladribine take a fundamentally different approach from drugs that need to be taken continuously. They are given in short, intensive courses that deeply deplete parts of the immune system, after which the immune system slowly rebuilds itself in a way that, ideally, no longer attacks myelin. Both preferentially wipe out memory B cells, which are thought to be key drivers of MS inflammation.¹⁰

The two drugs differ in how deep they cut. Alemtuzumab produces a more profound depletion of both T cells and B cells, and while B cells bounce back within about six months, T cells can take one to two years to recover to the low end of normal. Cladribine hits B cells harder relative to T cells, and the immune system recovers more quickly afterward. A practical consequence of alemtuzumab’s deeper T-cell depletion is that B cells sometimes overshoot during recovery, which can trigger secondary autoimmune conditions like thyroid disease. That B-cell overshoot has not been seen with cladribine.¹¹ The therapeutic effect of these drugs often persists well beyond the active treatment period, meaning many patients stay in remission for years without needing continuous medication, though a proportion eventually need retreatment.

Starting Strong Versus Stepping Up

One of the biggest debates in MS care is whether patients should start on a moderate-efficacy drug and escalate only if it fails, or go straight to a high-efficacy treatment from the beginning. Historically, most neurologists used an escalation approach: begin with an injectable or mild oral drug and switch to something stronger only after a relapse or new MRI lesions appeared. But a growing body of evidence favors the early high-efficacy strategy.

A comparison of national treatment approaches in Sweden and Denmark illustrates this starkly. Swedish neurologists tended to start patients on high-efficacy drugs early, while Danish neurologists more often escalated. After adjusting for patient differences, the Swedish approach was linked to a roughly 29% lower rate of confirmed disability worsening.¹² Several other matched-cohort studies have found similar results. In one, patients who started on high-efficacy drugs had about half the rate of conversion to secondary progressive MS compared with those who started on moderate-efficacy therapies after five years, and the gap widened further over nine years.¹³

The catch is that high-efficacy drugs carry higher risks of side effects and infections. The decision depends on how active someone’s disease is at diagnosis, their tolerance for risk, their plans for pregnancy, and how comfortable their neurologist is with aggressive early treatment. But the trend in the field is unmistakably moving toward earlier use of stronger therapies.

PML Risk With Natalizumab

The most feared safety issue in the MS drug landscape is progressive multifocal leukoencephalopathy, or PML, a rare but potentially fatal brain infection caused by the JC virus. Most people carry this virus harmlessly, but natalizumab’s powerful suppression of immune surveillance in the brain can allow the virus to reactivate. Risk increases with longer treatment duration and with prior use of other immunosuppressive drugs.¹⁴

A blood test for JC virus antibodies has become central to managing this risk. The test produces an antibody index: values below 0.4 are considered negative, 0.4 to 0.9 low risk, 0.9 to 1.5 medium risk, and above 1.5 high risk for developing PML.¹⁵ Expert guidelines recommend regular monitoring of this index, along with frequent MRI scans including specialized sequences, to catch early signs of PML before symptoms appear.¹⁶ In practice, many neurologists will switch patients off natalizumab if their JC antibody index climbs into the higher ranges.

Managing Relapses and Symptoms

DMTs aim to prevent future damage, but when a relapse strikes, short-term treatment focuses on speeding recovery. High-dose corticosteroids, given intravenously over three to five days, remain the standard approach for acute relapses and have broad regulatory approval for this purpose.¹⁷ They do not change the long-term course of the disease, but they can shorten and lessen the severity of a flare-up.

Separately, symptom-management medications address problems that persist between relapses. Fampridine (also called dalfampridine), a potassium channel blocker, can improve walking speed and endurance, but it works only in a subset of patients. Studies find that fewer than half of those who try it meet the threshold to be classified as responders.¹⁸ Other symptom treatments include medications for spasticity, neuropathic pain, bladder dysfunction, and fatigue, though evidence for some of these is thinner than many patients expect.

Vaccines and Immune-Suppressing Treatments

Because many MS drugs suppress parts of the immune system, vaccine responses can be blunted. This became acutely relevant during the COVID-19 pandemic. The impact varies dramatically by drug class. People taking interferons generally mount normal vaccine responses, while those on anti-CD20 therapies like ocrelizumab often produce much weaker antibody responses. In one study, only about 40% of ocrelizumab-treated patients developed detectable antibodies after mRNA COVID vaccination, compared with nearly all healthy controls.¹⁹

Fingolimod also reduced antibody responses and nearly eliminated the T-cell arm of the vaccine response in some studies. Teriflunomide, by contrast, appeared to have a minimal effect on seasonal influenza vaccination.²⁰ For people on anti-CD20 drugs, timing infusions so that vaccinations fall when B cells have had some time to recover can improve the odds of building a meaningful immune response. Delaying an infusion by three to six months before vaccination is one strategy that has been studied.²¹ Current guidance generally advises continuing DMTs during vaccination but adjusting the schedule for certain treatments.

Pregnancy and Breastfeeding

Pregnancy planning is a major concern for women with MS because most DMTs are either known to be unsafe during pregnancy or simply lack enough data to confirm safety. Clinical trials in MS have historically excluded pregnant and lactating women, which means labeling for most drugs either prohibits or discourages use during pregnancy, and required washout periods before conception vary widely between drugs.²² Some drugs, like teriflunomide, require an active elimination procedure before pregnancy because they linger in the body for months. Others, like natalizumab, are sometimes continued into early pregnancy in women with very active disease, though this is an off-label decision made case by case.

Breastfeeding raises a parallel challenge. Most DMTs are unlicensed during lactation because there is limited data on how much drug passes into breast milk and what effect it has on the infant. Women often face the difficult trade-off between the neurological benefits of resuming therapy quickly after delivery and the well-established advantages of breastfeeding.²³ The good news is that MS relapse rates tend to drop during pregnancy itself, though they often rebound in the months after delivery, making early treatment resumption important for many women.

MS Medications in Children

About 3 to 5% of MS cases begin before age 18. Children and adolescents with MS tend to have more frequent relapses than adults, making effective treatment especially important. A systematic review of clinical trials and observational studies found that all evaluated DMTs reduced relapse rates in pediatric-onset MS, but the high-efficacy drugs like natalizumab and fingolimod outperformed interferon beta.²⁴ Fingolimod is currently the only oral DMT with regulatory approval specifically for pediatric MS in most countries. Newer agents like dimethyl fumarate, teriflunomide, and ocrelizumab are increasingly used off-label in children and show promise in preventing disability accumulation.²⁵

Stem Cell Transplant

Autologous hematopoietic stem cell transplant, or AHSCT, is the most aggressive treatment option currently available for MS. It involves harvesting a patient’s own stem cells, using chemotherapy to wipe out the existing immune system, and then reinfusing the stem cells to rebuild it from scratch. It is not a traditional “medication,” but it has become a serious part of the treatment conversation for people with highly active relapsing MS who have not responded to or cannot tolerate conventional DMTs.

A large comparative study found that over five years, AHSCT was associated with fewer relapses than fingolimod and a greater chance of disability improvement. Compared with natalizumab, relapse rates were similar, but AHSCT still showed a higher probability of disability improvement. Against ocrelizumab, the two approaches looked broadly comparable over three years for both relapses and MRI activity. Treatment-related mortality occurred in about 0.6% of cases.²⁶ A single-center cohort study found that AHSCT showed lower relapse rates than both alemtuzumab and ocrelizumab, though disability progression was similar across groups.²⁷ AHSCT is not widely offered, and selecting the right candidate is critical. It tends to work best in younger patients with highly inflammatory disease and relatively little existing disability.

Tracking Treatment Response With Blood Biomarkers

One frustration in MS care has been the lack of a simple blood test to measure how well a treatment is working. MRI scans and clinical evaluations remain important, but they are expensive, time-consuming, and can miss subtle disease activity. Neurofilament light chain, a protein released from damaged nerve fibers, is emerging as a practical blood biomarker that fills some of this gap. When nerves are injured, neurofilament levels in the blood rise; effective treatment brings them down.

A consensus statement from an international expert group concluded that serum neurofilament light chain can now provide clinically useful information about both prognosis and treatment effectiveness alongside MRI.²⁸ In clinical trials, neurofilament levels correlated with lesion burden on MRI and dropped significantly within months of starting effective therapy. For example, fingolimod reduced blood neurofilament levels compared with both placebo and interferon, with the difference apparent by six months and sustained over the study period.²⁹ The test is inexpensive relative to MRI and can be repeated frequently, making it a potentially valuable tool for catching treatment failure early.³⁰

Drugs in the Pipeline

The next wave of MS medications includes Bruton’s tyrosine kinase inhibitors, commonly called BTK inhibitors. These are small molecules that can cross into the brain and target not only B cells but also microglia, the brain’s resident immune cells that are thought to drive smoldering inflammation behind the blood-brain barrier.³¹ Current anti-CD20 therapies like ocrelizumab are excellent at quelling relapses driven by circulating B cells, but they do not cross into the brain in meaningful amounts. BTK inhibitors could, in theory, address the component of MS progression that existing drugs miss. Several are in late-stage clinical trials, though results so far have been mixed, and safety signals around liver toxicity have complicated development for some candidates.

Beyond BTK inhibitors, research into primary progressive MS continues. Ocrelizumab remains the only approved therapy for that form of the disease, but agents like simvastatin, high-dose biotin, and coenzyme Q10 are under investigation, alongside experimental strategies like neuromodulation and anti-LINGO-1 antibodies aimed at promoting myelin repair rather than just suppressing inflammation.³²

Biosimilars and the Cost Problem

MS medications are among the most expensive drugs prescribed for any chronic condition, and cost is a real barrier to access worldwide. A year of treatment with a branded biologic DMT can run tens of thousands of dollars, and even oral therapies carry significant price tags. The entry of biosimilars and generic versions of older MS drugs is beginning to change this picture. Biosimilars for natalizumab and the interferons have reached the market in some countries, and the competitive pressure they create tends to lower the price of the originator drugs as well.³³ As more patents expire over the coming years, biosimilar competition is expected to expand access to effective treatment for people who currently cannot afford it or whose health systems ration these drugs by cost.³⁴

1
PubMed. Mechanisms of action of interferons and glatiramer acetate in multiple sclerosis ↩︎
2
PubMed Central. Interferon beta and glatiramer acetate therapy ↩︎
3
Neurotherapeutics. Sphingosine 1-phosphate Receptor Modulators for the Treatment of Multiple Sclerosis ↩︎
4
The Lancet. Sphingosine 1-phosphate receptor modulators in multiple sclerosis and other conditions ↩︎
5
PubMed. Insight into the mechanism of action of dimethyl fumarate in multiple sclerosis ↩︎
6
Pharmacological Reports. Mechanism of action of three newly registered drugs for multiple sclerosis treatment ↩︎
7
PubMed. Cutting edge: Natalizumab blocks adhesion but not initial contact of human T cells to the blood-brain barrier in vivo in an animal model of multiple sclerosis ↩︎
8
PubMed Central. Ocrelizumab and Other CD20+ B-Cell-Depleting Therapies in Multiple Sclerosis ↩︎
9
PubMed. B cell depletion in the treatment of multiple sclerosis ↩︎
10
PubMed Central. Pulsed immune reconstitution therapy in multiple sclerosis ↩︎
11
PubMed. Immunological consequences of “immune reconstitution therapy” in multiple sclerosis: A systematic review ↩︎
12
JAMA Neurology. Treatment Escalation vs Immediate Initiation of Highly Effective Treatment for Patients With Relapsing-Remitting Multiple Sclerosis: Data From 2 Different National Strategies ↩︎
13
PubMed Central. Escalation Versus Induction/High-Efficacy Treatment Strategies for Relapsing Multiple Sclerosis: Which is Best for Patients? ↩︎
14
PubMed. Risk stratification for progressive multifocal leukoencephalopathy in patients treated with natalizumab ↩︎
15
PubMed Central. Natalizumab-associated progressive multifocal leukoencephalopathy ↩︎
16
Journal of Neurology, Neurosurgery & Psychiatry. Stratification and monitoring of natalizumab-associated progressive multifocal leukoencephalopathy risk: recommendations from an expert group ↩︎
17
PubMed Central. Treatment of acute relapses in multiple sclerosis ↩︎
18
PubMed. The effect of symptom-controlling medication on gait outcomes in people with multiple sclerosis: a systematic review ↩︎
19
PubMed Central. Humoral- and T-Cell-Specific Immune Responses to SARS-CoV-2 mRNA Vaccination in Patients With MS Using Different Disease-Modifying Therapies ↩︎
20
PubMed Central. Vaccine Response in Patients With Multiple Sclerosis Receiving Teriflunomide ↩︎
21
JAMA Neurology. Association of Disease-Modifying Treatment and Anti-CD20 Infusion Timing With Humoral Response to 2 SARS-CoV-2 Vaccines in Patients With Multiple Sclerosis ↩︎
22
PubMed Central. Practical Considerations for Managing Pregnancy in Patients With Multiple Sclerosis: Dispelling the Myths ↩︎
23
PubMed Central. Disease-Modifying Drugs and Breastfeeding in Multiple Sclerosis: A Narrative Literature Review ↩︎
24
PubMed. Efficacy and safety of disease-modifying therapies in pediatric-onset multiple sclerosis: A systematic review of clinical trials and observational studies ↩︎
25
PubMed Central. Therapeutic Advances in Pediatric Multiple Sclerosis ↩︎
26
JAMA Neurology. Comparative Effectiveness of Autologous Hematopoietic Stem Cell Transplant vs Fingolimod, Natalizumab, and Ocrelizumab in Highly Active Relapsing-Remitting Multiple Sclerosis ↩︎
27
PubMed Central. Effectiveness of Autologous Hematopoietic Stem Cell Transplantation versus Alemtuzumab and Ocrelizumab in Relapsing Multiple Sclerosis: A Single Center Cohort Study ↩︎
28
eBioMedicine. Neurofilament light chain as a biomarker in multiple sclerosis — A consensus statement ↩︎
29
PubMed Central. Blood neurofilament light chain as a biomarker of MS disease activity and treatment response ↩︎
30
PubMed Central. Neurofilament Light Chain and Multiple Sclerosis: Building a Neurofoundational Model of Biomarkers and Diagnosis ↩︎
31
PubMed. Targeting B Cells and Microglia in Multiple Sclerosis With Bruton Tyrosine Kinase Inhibitors: A Review ↩︎
32
PubMed Central. Primary Progressive Multiple Sclerosis: New Therapeutic Approaches ↩︎
33
PubMed Central. Generics, Biosimilar and Follow-On Non-Biologic Complex Drugs for Multiple Sclerosis: A Narrative Review of the Regulatory and Clinical Implications for European Neurologists ↩︎
34
PubMed. A place for biosimilars in the changing multiple sclerosis treatment landscape ↩︎